Company

PEP-Therapy is a medical biotechnology company, which develops peptides as targeted therapies for severe diseases, with an initial focus on cancer.

PEP-Therapy has developed a proprietary Cell Penetrating and Interfering Peptides (CP&IP) technology for the development of its therapeutic products. These innovative peptides penetrate cells and then specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.

Founded in January 2014, PEP-Therapy is building on research  from Inserm (the French National Institute of Health), Institut Curie and Sorbonne University.

PEP-Therapy has a pipeline of CP&IP-based drug candidates. Its first anti-cancer product, PEP-010, is in the final stages of preparation prior to Phase I/II clinical studies in 2020.

PEP-Therapy raised 2.5 M€ to date from Seventure Partners (Quadrivium 1 seed fund) and a personal investment from Dr Bernard Majoie former Chairman and CEO of Laboratoires Fournier and Founding Chairman of Fondation Fournier-Majoie pour l'Innovation (FFMI).

Since incorporation, PEP-Therapy has also been awarded several non-dilutive grants:

• to develop PEP-010 up to Phase I/II clinical trials (French Ministries of Industry and Research grant);

• to develop new therapeutics for uveal melanoma (European Horizon 2020 grant).